| Identification | Back Directory | [Name]
LIT-001 free base | [CAS]
2245072-20-0 | [Synonyms]
LIT-001 free base
1-Pyrrolidinecarboxamide, N-[[4-[(4,10-dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-2-[(dimethylamino)thioxomethyl]-, (2S)- | [Molecular Formula]
C28H33N7O2S | [MDL Number]
MFCD33029220 | [MOL File]
2245072-20-0.mol | [Molecular Weight]
531.67 |
| Hazard Information | Back Directory | [Description]
LIT-001 is the first potent nonpeptide agonist of oxytocin receptor (OT-R). | [Uses]
LIT-001 free base is the first nonpeptide oxytocin receptor (OT-R) agonist (EC50=55 nM; Ki=226 nM). LIT-001 free base improves social interaction in a mouse model of autism[1]. | [in vivo]
LIT-001 free base (10-20 mg/kg; i.p.) alleviates core symptoms in the context of autism spectrum disorders (ASD )[1]. | Animal Model: | Oprm1–/– mice (bred in house on a 50% 129SVPas–50% C57BL/6J hybrid background)[1] | | Dosage: | 10, 20 mg/kg | | Administration: | i.p. | | Result: | Alleviated core symptoms in the context of ASD. |
| [References]
[1] Frantz MC, et al. LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. J Med Chem. 2018 Oct 11;61(19):8670-8692. DOI:10.1021/acs.jmedchem.8b00697 |
|
| Company Name: |
cjbscvictory
|
| Telephone: |
13348960310 13348960310 |
| Website: |
www.weikeqi-biotech.com/ |
|